Gosset Anion exchange protein 1, erythrocyte Overview
Anion exchange protein 1, erythrocyte (commonly known as Band 3 or AE1), is the major membrane glycoprotein of human erythrocytes and also present in the kidney. It is a member of the solute carrier family 4 (SLC4A1) that mediates the electroneutral exchange of chloride and bicarbonate ions across the plasma membrane. This function is essential for CO₂ transport in the bloodstream and for acid-base balance in the kidney. Structurally, Band 3 is a dimer with a cytosolic N-terminal domain that interacts with the cytoskeleton (ankyrin, protein 4.2) and various red cell proteins (e.g., hemoglobin, glycolytic enzymes), and a C-terminal multi-pass transmembrane domain responsible for anion exchange. Mutations in its encoding gene SLC4A1 lead to hereditary spherocytosis, Southeast Asian ovalocytosis, and distal renal tubular acidosis. Band 3 is a known target for inhibitors such as DIDS and DEPC, but due to its vital physiological functions, therapeutic targeting presents significant safety challenges[1][3][4][5][6][8][10].
Mechanism of Action
Inhibition of Cl⁻/HCO₃⁻ exchange activity (blockade of anion transport) Blockade of conformational changes required for transport
Biological Functions
Disease Associations
Safety Considerations
- Essential role in red blood cell structure and gas transport implies high risk of hemolysis, anemia, or acid-base disturbances if targeted systemically
- Mutations or dysregulation cause hemolytic anemia and kidney acidification defects
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Band 3 modifications (mutations or abnormal glycosylation) are diagnostic for several hereditary red blood cell disorders |
| SLC4A1 mutation detection in hereditary spherocytosis and distal renal tubular acidosis |